Skip to main content
SpringerLink
Log in

Current Practices and Awareness of Anticancer Plants in the Traditional Healthcare System

  • Chapter
  • First Online:
Anticancer plants: Properties and Application

  • 919 Accesses

Abstract

Nowadays, the increasing burden of cancer has renewed the interest in plants as source of potential anticancer drugs. In fact, one of the major problems with cancer chemotherapy is the extreme toxicity of the traditional drugs. Thus, the research for new biologically active molecules against cancer is targeted on plants and their derived natural products. Plants used in traditional medicine have proved effective and safe in the treatment and management of cancers, and almost 80% of the world’s population use anticancer agents of natural origin. Thus, the aim of the present chapter is to highlight the plant-derived natural products and their analogues established as anticancer agents in the traditional and current medicinal practices, their toxicological effects, and clinical exercises along with the new technologies applied for delivering natural anticancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, Oakes M, McGuire W, Reed E, Gibbs H (1993) A reassessment of cardiac toxicity associated with Taxol. J Nat Cancer Inst Monogr 15:117–130

    Google Scholar 

  • Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001–1012

    Article  CAS  PubMed  Google Scholar 

  • Beretta GL, Gatti L, Perego P, Zaffaroni N (2013) Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem 20:1541–1565

    Article  CAS  PubMed  Google Scholar 

  • Brooks DJ, Srinivas NR, Alberts DS, Thomas T, Igwemzie LM, McKinney LM, Randolph J, Schacter L, Kaul S, Barbhaiya RH (1995) Phase I and pharmacokinetic study of etoposide phosphate. Anti-Cancer Drugs 6:637–644

    Article  CAS  PubMed  Google Scholar 

  • Brooks TA, Minderman H, O’Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195–1205

    PubMed  CAS  Google Scholar 

  • Burke TG, Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40–46

    Article  CAS  PubMed  Google Scholar 

  • Canel C, Moraes RM, Dayan FE, Ferreira D (2000) Podophyllotoxin. Phytochemistry 54:115–120

    Article  CAS  PubMed  Google Scholar 

  • Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60:319–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen SH, Chan NL, Hsieh TS (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82:139–170

    Article  CAS  PubMed  Google Scholar 

  • Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114

    Article  CAS  PubMed  Google Scholar 

  • Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643–2655

    Article  CAS  PubMed  Google Scholar 

  • Cragg GM, Newman DJ (2004) A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 67:232–244

    Article  CAS  PubMed  Google Scholar 

  • Dallavalle S, Giannini G, Alloatti D, Casati A, Marastoni E, Musso L, Merlini L, Morini G, Penco S, Pisano C, Tinelli S, De Cesare M, Beretta GL, Zunino F (2006) Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem 49:5177–5186

    Article  CAS  PubMed  Google Scholar 

  • Damayanthi Y, Lown JW (1998) Podophyllotoxins: current status and recent developments. Curr Med Chem 5:205–252

    PubMed  CAS  Google Scholar 

  • Dancey J, Steward WP (1995) The role of vindesine in oncology-recommendations after 10 years’ experience. Anti-Cancer Drugs 6:625–636

    Article  CAS  PubMed  Google Scholar 

  • Desbene S, Giorgi-Renault S (2002) Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues. Curr Med Chem Anticancer Agents 2:71–90

    Article  CAS  PubMed  Google Scholar 

  • Eklund JW, Trifilio S, Mulcahy MF (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology 19:1057–1063

    PubMed  Google Scholar 

  • Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9:2444–2453

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fanale D, Bronte G, Passiglia F, Calo V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listi A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V (2015) Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option. Anal Cell Pathol 2015:690916

    Article  CAS  Google Scholar 

  • Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221–253

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–661

    PubMed  CAS  Google Scholar 

  • Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J (1999) A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69–75

    PubMed  CAS  Google Scholar 

  • Gerullis H, Wawroschek F, Kohne CH, Ecke TH (2017) Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol 9:28–35

    Article  CAS  PubMed  Google Scholar 

  • Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, Orcutt C, Winograd B, Scadden DT (1999) Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 17:1876–1883

    Article  CAS  PubMed  Google Scholar 

  • Gordaliza M, Castro MA, del Corral JM, Feliciano AS (2000) Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des 6:1811–1839

    Article  CAS  PubMed  Google Scholar 

  • Gueritte-Voegelein F, Guenard D, Dubois J, Wahl A, Potier P (1994) Chemical and biological studies on Taxol (Paclitaxel) and Taxotere (Docetaxel), new antineoplastic agents. J Pharm Belg 49:193–205

    PubMed  CAS  Google Scholar 

  • Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502–1510

    Article  CAS  PubMed  Google Scholar 

  • Habli Z, Toumieh G, Fatfat M, Rahal ON, Gali-Muhtasib H (2017) Emerging cytotoxic alkaloids in the battle against cancer: overview of molecular mechanisms. Molecules 22:250

    Article  CAS  PubMed Central  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  • Hande KR (1992) Etoposide pharmacology. Semin Oncol 19:3–9

    PubMed  CAS  Google Scholar 

  • Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514–1521

    Article  CAS  PubMed  Google Scholar 

  • Hari M, Wang Y, Veeraraghavan S, Cabral F (2003) Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2:597–605

    PubMed  CAS  Google Scholar 

  • Harmon BV, Takano YS, Winterford CM, Potten CS (1992) Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt’s lymphoma cell line. Cell Prolif 25:523–536

    Article  CAS  PubMed  Google Scholar 

  • Hartmann JT, Lipp HP (2006) Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II – mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 29:209–230

    Article  CAS  PubMed  Google Scholar 

  • Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715–720

    Article  CAS  PubMed  Google Scholar 

  • Himes RH (1991) Interactions of the Catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257–267

    Article  CAS  PubMed  Google Scholar 

  • Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726

    PubMed  CAS  Google Scholar 

  • Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044

    PubMed  CAS  Google Scholar 

  • Imbert TF (1998) Discovery of podophyllotoxins. Biochimie 80:207–222

    Article  CAS  PubMed  Google Scholar 

  • Jackson DV Jr, Richards F 2nd, Spurr CL, Long TR, Rardin DA, Albertson DA, Sterchi JM (1984) Hepatic intra-arterial infusion of vincristine. Cancer Chemother Pharmacol 13:120–122

    PubMed  Google Scholar 

  • Jackson DV Jr, McMahan RA, Pope EK, Case LD, Cooper MR, Kaplon MK, Richards F 2nd, Stuart JJ, White DR, Zekan PJ (1986) Clinical trial of folinic acid to reduce vincristine neurotoxicity. Cancer Chemother Pharmacol 17:281–284

    Article  PubMed  Google Scholar 

  • Joel S (1996) The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use. Cancer Treat Rev 21:513–525

    Article  CAS  PubMed  Google Scholar 

  • Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr (1963) The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–1427

    PubMed  CAS  Google Scholar 

  • Kelly M, Hartwell JL (1954) The biological effects and the chemical composition of podophyllin: a review. J Nat Cancer Inst 14:967–1010

    PubMed  CAS  Google Scholar 

  • Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Jpn Lung Cancer Group J Clin Oncol 16:1068–1074

    CAS  Google Scholar 

  • Kumar S, Mahdi H, Bryant C, Shah JP, Garg G, Munkarah A (2010) Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health 2:411–427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lautier D, Canitrot Y, Deeley RG, Cole SP (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967–977

    Article  CAS  PubMed  Google Scholar 

  • Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM (1991) Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51:5275–5283

    PubMed  CAS  Google Scholar 

  • Markman M, Rose PG, Jones E, Horowitz IR, Kennedy A, Webster K, Belinson J, Fusco N, Fluellen L, Kulp B, Peterson G, McGuire WP (1998) Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 16:1849–1851

    Article  CAS  PubMed  Google Scholar 

  • Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296–1302

    PubMed  CAS  Google Scholar 

  • Martino E, Della Volpe S, Terribile E, Benetti E, Sakaj M, Centamore A, Sala A, Collina S (2017) The long story of camptothecin: from traditional medicine to drugs. Bioorg Med Chem Lett 27:701–707

    Article  CAS  PubMed  Google Scholar 

  • Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K (2005) Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843–4850

    Article  CAS  PubMed  Google Scholar 

  • Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, Gianni L (2001) Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7:1511–1515

    PubMed  CAS  Google Scholar 

  • Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730

    Article  CAS  PubMed  Google Scholar 

  • Mitchison TJ (1993) Localization of an exchangeable GTP binding site at the plus end of microtubules. Science 261:1044–1047

    Article  CAS  PubMed  Google Scholar 

  • Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663

    Article  CAS  PubMed  Google Scholar 

  • Morin PJ (2003) Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6:169–172

    Article  CAS  PubMed  Google Scholar 

  • Nachman J (1990) Therapy for childhood non-Hodgkin’s lymphomas, nonlymphoblastic type. Review of recent studies and current recommendations. J Pediatr Hematol Oncol 12:359–366

    Article  CAS  Google Scholar 

  • Nayak MS, Yang JM, Hait WN (2007) Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67:5831–5839

    Article  CAS  PubMed  Google Scholar 

  • Newman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79:629–661

    Article  CAS  PubMed  Google Scholar 

  • Nightingale G, Ryu J (2012) Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T 37:440–448

    PubMed  PubMed Central  Google Scholar 

  • Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22:7280–7295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paller CJ, Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Dev Ther 5:117–124

    CAS  Google Scholar 

  • von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667

    Article  Google Scholar 

  • Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15:633–638

    Article  PubMed  Google Scholar 

  • Perdue RE Jr, Abbott BJ, Hartwell JL (1970) Screening plants for antitumor activity. II. A comparison of two methods of sampling herbaceous plants. Lloydia 33:1–6

    PubMed  CAS  Google Scholar 

  • Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789–802

    Article  CAS  PubMed  Google Scholar 

  • Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J, Cano JP (1987) Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Res 47:5796–5799

    PubMed  CAS  Google Scholar 

  • Rebucci M, Michiels C (2013) Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 85:1219–1226

    Article  CAS  PubMed  Google Scholar 

  • Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S (1996) Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59:32–40

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK (1995) The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices. J Infus Chemother 5:173–178

    PubMed  CAS  Google Scholar 

  • Rowinsky EK, Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35–84

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH et al (1992a) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647–656

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992b) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–662

    PubMed  CAS  Google Scholar 

  • Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.Annu Rev Med. 1997;48:353-74.

    Google Scholar 

  • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Eng J Med 343:905–914

    Article  CAS  PubMed  Google Scholar 

  • Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J Clin Oncol 32:2039–2049

    Article  CAS  PubMed  Google Scholar 

  • Shimoyama M, Murata Y, Sumi KI, Hamazoe R, Komuro I (2001) Docetaxel induced cardiotoxicity. Heart 86:219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40:S13–S19

    Article  CAS  PubMed  Google Scholar 

  • Spicakova T, O’Brien MM, Duran GE, Sweet-Cordero A, Sikic BI (2010) Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 9:2970–2981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stanton RA, Gernert KM, Nettles JH, Aneja R (2011) Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 31:443–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534–1541

    Article  CAS  PubMed  Google Scholar 

  • Szebeni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Nat Cancer Inst 90:300–306

    Article  CAS  PubMed  Google Scholar 

  • Thomas CJ, Rahier NJ, Hecht SM (2004) Camptothecin: current perspectives. Bioorg Med Chem 12:1585–1604

    Article  CAS  PubMed  Google Scholar 

  • Tsukidate K, Yamamoto K, Snyder JW, Farber JL (1993) Microtubule antagonists activate programmed cell death (apoptosis) in cultured rat hepatocytes. J Pathol 143:918–925

    CAS  Google Scholar 

  • Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Can Chemother Pharmacol 8:215–219

    Article  Google Scholar 

  • Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19:1501–1518

    Article  CAS  PubMed  Google Scholar 

  • Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P, Besterman JM (1993) Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 36:2689–2700

    Article  CAS  PubMed  Google Scholar 

  • Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440

    Article  CAS  PubMed  Google Scholar 

  • Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat Med 5:412–417

    Article  CAS  PubMed  Google Scholar 

  • Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327

    Article  CAS  PubMed  Google Scholar 

  • WHO (2016) Cancer fact sheets (http://www.who.int/cancer/en/; Assessed on 31st July 2017)

  • Yadav S, Gupta S (2015) Development and in vitro characterization of docetaxel-loaded ligand appended solid fat nanoemulsions for potential use in breast cancer therapy. Artif Cells Nanomed Biotechnol 43:93–102

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto Y, Kawano I, Iwase H (2011) Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 4:123–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yassine F, Salibi E, Gali-Muhtasib H (2016) Overview of the formulations and analogs in the Taxanes’ story. Curr Med Chem 23:4540–4558

    Article  CAS  PubMed  Google Scholar 

  • Yuan H, Ma Q, Ye L, Piao G (2016) The traditional medicine and modern medicine from natural products. Molecules 21:E559

    Article  CAS  PubMed  Google Scholar 

  • Zeffren J, Yagoda A, Kelsen D, Winn R (1984) Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. Anticancer Res 4:411–413

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, University of Naples Federico II, Naples, Italy

    Paola De Cicco, Elisabetta Panza, Chiara Armogida, Giuseppe Ercolano, Giuseppe Cirino & Angela Ianaro

Authors
  1. Paola De Cicco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Panza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Armogida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Ercolano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Cirino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angela Ianaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela Ianaro .

Editor information

Editors and Affiliations

  1. Department of Botany, Gandhi Faiz-e-Aam College, Shahjahanpur, Uttar Pradesh, India

    Mohd Sayeed Akhtar

  2. Department of Crop Science Faculty of Agriculture, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

    Mallappa Kumara Swamy

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Cicco, P., Panza, E., Armogida, C., Ercolano, G., Cirino, G., Ianaro, A. (2018). Current Practices and Awareness of Anticancer Plants in the Traditional Healthcare System. In: Akhtar, M., Swamy, M. (eds) Anticancer plants: Properties and Application. Springer, Singapore. https://doi.org/10.1007/978-981-10-8548-2_1

Download citation

Publish with us

Policies and ethics

Search

Navigation